CTLA4 and cancer: Current immune–checkpoint blockade (ICB)-based immunotherapies, commonly targeting PD-1, PD-L1 and CTLA-4, have not achieved the desired efficacy in the therapeutic practices in different types of cancers, suggesting that tumor cells may develop other ways to evade immune surveillance.